Notice of Intent to Sole Source; Monument Medical
ID: 25-000116Type: Special Notice
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH - CCBETHESDA, MD, 20892, USA

NAICS

Surgical and Medical Instrument Manufacturing (339112)

PSC

MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES (6515)

Set Aside

Total Small Business Set-Aside (FAR 19.5) (SBA)

Original Source

https://sam.gov/opp/65b3f50ad556415db187d3eea9070be6/view
Timeline
    Description

    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to award a sole source contract to QuVA Pharma, Inc. for the procurement of compounded intravenous (IV) narcotics for patient care at the NIH Clinical Center. This acquisition aims to secure sterile compounded products that meet the quality standards necessary for ongoing patient treatment, as QuVA Pharma is the sole distributor of these specific IV narcotics in the U.S. market. Interested parties are invited to express their interest and capabilities regarding this procurement, with comments due by November 15, 2024, at 10 AM EST, directed to Kristin Nagashima at kristin.nagashima@nih.gov.

    Point(s) of Contact
    Kristin Nagashima
    kristin.nagashima@nih.gov
    Files
    No associated files provided.
    Lifecycle
    Title
    Type
    Notice of Intent to Sole Source; Monument Medical
    Currently viewing
    Special Notice
    Similar Opportunities
    PREPARATION AND DISTRIBUTION OF RESEARCH DRUG PRODUCTS
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institute on Drug Abuse (NIDA), is seeking proposals for the "Preparation and Distribution of Research Drug Products" under solicitation number 75N95024R00003. The primary objective of this procurement is to acquire, analyze, manufacture, and distribute a variety of drug compounds, including controlled substances, to support drug abuse and addiction research. This contract, structured as an indefinite delivery, indefinite quantity (IDIQ) agreement, is expected to span five years and will allow for both cost reimbursement and fixed-price task orders based on NIDA's needs. Interested offerors must submit their proposals electronically by November 15, 2024, and ensure compliance with federal acquisition regulations, including maintaining active registration in the System for Award Management (SAM). For further inquiries, potential bidders can contact Scott Duernberger at scott.duernberger@nih.gov or Josh Lazarus at josh.lazarus@nih.gov.
    Chemistry, Manufacturing and Controls and Related Services for Development of Drug Substances
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is soliciting proposals for Chemistry, Manufacturing, and Controls (CMC) services related to the development of drug substances, as outlined in RFP Number 75N95024R00094. The primary objective is to ensure the provision of high-quality drug substances to support preclinical and Investigational New Drug (IND)-enabling studies, which are critical for advancing therapeutic innovations. This opportunity emphasizes compliance with current Good Manufacturing Practices (cGMP) and requires detailed reporting and documentation throughout the contract period. Interested contractors should note that the proposal submission deadline is December 3, 2024, with a maximum funding amount of $49.7 million anticipated for the contract period from September 1, 2025, to May 14, 2031. For further inquiries, potential bidders can contact Samson Shifaraw at samson.shifaraw@nih.gov or Valerie Whipple at valerie.whipple@nih.gov.
    NIAID CLINICAL PRODUCTS CENTER (CPC)
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for a contract to provide pharmacy and pharmaceutical oversight for clinical trials, both nationally and internationally. The primary objective of this contract is to ensure the integrity of study products, participant safety, and compliance with pharmacy and pharmaceutical regulations throughout various NIH-funded clinical trials. This opportunity is critical for maintaining high standards in public health research, as it encompasses a wide range of services including product management, regulatory document maintenance, and clinical laboratory testing. Proposals are due by January 17, 2025, with the contract expected to commence on April 1, 2026, and run through March 31, 2027, potentially extending through 2033. Interested parties can contact Deborah Blyveis at blyveisd@niaid.nih.gov or Emily Bannister at emily.bannister@nih.gov for further information.
    Notice of Intent to Sole Source; Infor Software
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to award a sole source contract to Infor (US), LLC for the maintenance software license, maintenance, and support of Infor / Lawson Applications at the NIH Clinical Center in Bethesda, Maryland. This acquisition is crucial for ensuring the continued operation and support of various software modules utilized within the NIH, including financial management and inventory control systems, which are essential for the center's clinical and administrative functions. The contract will be awarded under the Federal Acquisition Regulation (FAR) Part 13, with a total value not exceeding $7.5 million, and interested parties may submit their capabilities and interest to the primary contact, Kristin Nagashima, via email by November 1, 2024, at 10 AM EST.
    Gibco EXPI293 Expression Media 6 x 1L, catalog # A1435102 and 2) EXPIFECTAMINE TRANSFXN KIT 10L 10L Kit Catalog# A14525
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking quotes for the procurement of specific commercial items, namely the EXPI293 Expression Medium and the Expifectamine Transfection Kit, under solicitation number RFQ-NIAID-25-2244965. The procurement involves a total of 36 units of the expression medium to be delivered in six scheduled shipments from January to November 2025, along with one delivery of ten transfection kits, all adhering to strict quality and expiration date criteria. These products are critical for biological research and development, particularly in the fields of allergy and infectious diseases. Interested vendors must submit their proposals by October 30, 2023, via the NIH's electronic Simplified Acquisition Submission System (eSASS), and are required to be registered in the System for Award Management (SAM) prior to submission. For further inquiries, contact Calvin Robinson at calvin.robinson@nih.gov or by phone at 406-363-9214.
    770-25-1-801-0016 -National CMOP NALTREXONE -(VA-25-00010070)
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking qualified vendors to provide Naltrexone tablets as part of a procurement initiative under solicitation number 36C77025Q0036. Vendors are required to submit their quotes by 4:00 PM CT on October 28, 2024, and must include essential documentation such as a signed SF1449 Solicitation cover page, a completed quote spreadsheet, and compliance with the Drug Supply Chain Security Act. This procurement is critical for ensuring the availability of pharmaceuticals necessary for the healthcare of veterans, reflecting the government's commitment to quality service. Interested vendors can contact Jennifer L. Knight at jennifer.knight@va.gov or by phone at 913-684-0162 for further information.
    Qiagen LLC DNA Isolation Kits
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to procure DNA Isolation Kits from Qiagen LLC on a sole source basis. The acquisition aims to supply the Human Leukocyte Antigen (HLA) Lab with essential testing kits that have been rigorously tested to ensure high-quality DNA samples for critical patient testing. These kits are vital for HLA typing, particularly for critically ill patients, as they directly impact the turnaround time for results necessary for lifesaving transplants. Interested parties may submit their capability statements to Shasheshe Goolsby at shasheshe.goolsby@nih.gov by October 31, 2024, at 6:30 AM EST, as this is not a request for proposals.
    Title: Global Life Sciences Sepax Cell Separation Kits
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to award a firm fixed-price contract for the procurement of Global Life Sciences Sepax Cell Separation Kits and Ficoll Paque Premium reagents. The NIH's Department of Transfusion Medicine requires these items to support the manufacturing of cell-based therapies for patients with advanced metastatic cancer, utilizing the Sepax C-Pro Cell Processing Instruments. This acquisition is being conducted under the Simplified Acquisition Procedures, allowing for a sole-source award to Cytiva-Global Life Sciences Solutions USA LLC, with capability statements due by November 3, 2024, at 12:00 PM EST. Interested parties can direct inquiries to Sheri Eiri at sheri.eiri@nih.gov.
    Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH) through the National Center for Advancing Translational Sciences (NCATS), is seeking qualified small businesses to provide Chemistry, Manufacturing, and Controls (CMC) and related services for the development of drug products. The objective of this procurement is to support the Therapeutic Development Branch in ensuring the delivery of drug products of sufficient quality and quantity for preclinical, IND-enabling, and clinical studies, which are critical for advancing therapeutic candidates through the drug development pipeline. This opportunity is part of a Small Business Sources Sought notice, aimed at gathering information on the capabilities of small businesses to fulfill these requirements, with a focus on compliance with applicable regulations and the potential for a multiple-award Indefinite Delivery/Indefinite Quantity (IDIQ) contract. Interested vendors must submit their capability statements by 10:00 AM Eastern Time on July 21, 2024, to Michelle Cecilia at michelle.cecilia@nih.gov.
    DocuWare License and Annual Maintenance and Software Support Services
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to award a firm-fixed price contract for DocuWare License and Annual Maintenance and Software Support Services. This procurement aims to provide ongoing support for the DocuWare software system, which is critical for managing over 80,000 active medical and donor records within the Department of Transfusion Medicine, ensuring compliance with federal regulations. The NIH has determined that only DocuWare Corporation can fulfill this requirement without incurring significant costs associated with transitioning to a new vendor, including retraining and system redevelopment. Interested parties may express their interest and capabilities to Tasha Lowe at lowet2@mail.nih.gov by November 4, 2024, at 12 PM.